Aptahem AB (publ) (NGM:APTA)

Market Cap	9.05M -59.7%
Revenue (ttm)	n/a
Net Income	-5.84M
EPS	-0.23
Shares Out	25.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	526,344
Open	0.3640
Previous Close	0.3220
Day's Range	0.3350 - 0.3980
52-Week Range	0.2770 - 1.9500
Beta	0.70
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 5, 2026

About Aptahem AB

Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 19, 2026

Data Sources Report a data error